Last updated on September 2014

Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer


Brief description of study

The objective of this study is to assess efficacy and safety of radium 223 dichloride in subjects with human epidermal growth factor receptor 2 (HER2) negative hormone receptor positive breast cancer with bone metastases treated with exemestane and everolimus.

Clinical Study Identifier: NCT02258451

Find a site near you

Start Over

Bayer Clinical Trials Contact

Kowloon, Hong Kong
4.2miles
  Connect »

Bayer Clinical Trials Contact

New Territories, Hong Kong
4.75miles
  Connect »

Bayer Clinical Trials Contact

Hong Kong, Hong Kong
5.77miles
  Connect »

Bayer Clinical Trials Contact

Chai wan, Hong Kong
7.95miles
  Connect »